HRP20140611T1 - Inhibitori kinaze p70 s6 - Google Patents

Inhibitori kinaze p70 s6 Download PDF

Info

Publication number
HRP20140611T1
HRP20140611T1 HRP20140611AT HRP20140611T HRP20140611T1 HR P20140611 T1 HRP20140611 T1 HR P20140611T1 HR P20140611A T HRP20140611A T HR P20140611AT HR P20140611 T HRP20140611 T HR P20140611T HR P20140611 T1 HRP20140611 T1 HR P20140611T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
intended
trifluoromethyl
Prior art date
Application number
HRP20140611AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L. Holst
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20140611T1 publication Critical patent/HRP20140611T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20140611AT 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6 HRP20140611T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20140611T1 true HRP20140611T1 (hr) 2014-08-15

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140611AT HRP20140611T1 (hr) 2007-05-11 2008-05-01 Inhibitori kinaze p70 s6

Country Status (33)

Country Link
US (2) US8093383B2 (Direct)
EP (1) EP2148880B1 (Direct)
JP (1) JP5503532B2 (Direct)
KR (1) KR101088219B1 (Direct)
CN (1) CN101679439B (Direct)
AR (1) AR066344A1 (Direct)
AU (1) AU2008251692B2 (Direct)
BR (1) BRPI0811212A2 (Direct)
CA (1) CA2687265C (Direct)
CL (1) CL2008001230A1 (Direct)
CO (1) CO6241109A2 (Direct)
CR (1) CR11106A (Direct)
DK (1) DK2148880T3 (Direct)
DO (1) DOP2009000257A (Direct)
EA (1) EA016445B1 (Direct)
EC (1) ECSP099721A (Direct)
ES (1) ES2483726T3 (Direct)
GT (1) GT200900292A (Direct)
HR (1) HRP20140611T1 (Direct)
IL (1) IL201564A (Direct)
MA (1) MA31433B1 (Direct)
MX (1) MX2009012075A (Direct)
MY (1) MY154898A (Direct)
NZ (1) NZ580423A (Direct)
PE (1) PE20090887A1 (Direct)
PL (1) PL2148880T3 (Direct)
PT (1) PT2148880E (Direct)
RS (1) RS53451B (Direct)
SI (1) SI2148880T1 (Direct)
TN (1) TN2009000446A1 (Direct)
TW (1) TWI423805B (Direct)
UA (1) UA99284C2 (Direct)
WO (1) WO2008140947A1 (Direct)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2355821A1 (en) * 2008-11-11 2011-08-17 Eli Lilly and Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
EA018824B1 (ru) * 2008-11-11 2013-10-30 Эли Лилли Энд Компани КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРОМ КИНАЗЫ p70 S6 И ИНГИБИТОРОМ mTOR
JP5642714B2 (ja) 2009-02-11 2014-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規なアミノアザヘテロ環式カルボキサミド
BR112012002336A2 (pt) 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
WO2012016001A1 (en) 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015149909A1 (en) 2014-04-03 2015-10-08 Merck Patent Gmbh Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR20230110296A (ko) 2020-11-16 2023-07-21 메르크 파텐트 게엠베하 암 치료를 위한 키나제 억제제 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EP2148880B1 (en) 2014-05-28
CL2008001230A1 (es) 2009-05-22
PE20090887A1 (es) 2009-07-13
WO2008140947A1 (en) 2008-11-20
RS53451B (sr) 2014-12-31
CN101679439A (zh) 2010-03-24
TN2009000446A1 (en) 2011-03-31
ES2483726T3 (es) 2014-08-07
AU2008251692B2 (en) 2012-10-11
US8093383B2 (en) 2012-01-10
ECSP099721A (es) 2009-12-28
IL201564A (en) 2014-08-31
MX2009012075A (es) 2009-11-19
CR11106A (es) 2010-04-12
CA2687265C (en) 2012-12-04
KR20100005710A (ko) 2010-01-15
MY154898A (en) 2015-08-28
JP5503532B2 (ja) 2014-05-28
US20090163714A1 (en) 2009-06-25
CA2687265A1 (en) 2008-11-20
MA31433B1 (fr) 2010-06-01
AU2008251692A1 (en) 2008-11-20
AR066344A1 (es) 2009-08-12
KR101088219B1 (ko) 2011-11-30
EP2148880A1 (en) 2010-02-03
PL2148880T3 (pl) 2014-10-31
UA99284C2 (ru) 2012-08-10
US20120071490A1 (en) 2012-03-22
JP2010526814A (ja) 2010-08-05
GT200900292A (es) 2011-06-24
NZ580423A (en) 2012-02-24
IL201564A0 (en) 2010-05-31
DOP2009000257A (es) 2010-03-31
CO6241109A2 (es) 2011-01-20
CN101679439B (zh) 2013-09-11
HK1140767A1 (en) 2010-10-22
PT2148880E (pt) 2014-08-28
TWI423805B (zh) 2014-01-21
DK2148880T3 (da) 2014-06-16
EA016445B1 (ru) 2012-05-30
TW200848053A (en) 2008-12-16
SI2148880T1 (sl) 2014-07-31
EA200971051A1 (ru) 2010-06-30
BRPI0811212A2 (pt) 2014-10-29

Similar Documents

Publication Publication Date Title
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
MY150519A (en) Imidazoquinolines with immuno-modulating properties
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
HRP20221154T1 (hr) Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
RU2012148133A (ru) Комбинация, включающая ингибитор циклинзависимой киназы 4 или циклинзависимой киназы 6 (cdk4/6) и ингибитор mtor, для лечения рака
SE0402735D0 (sv) Novel compounds
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
HRP20140481T1 (hr) SUPSTITUIRANI SPOJEVI IMIDAZO[1,2-b]PIRIDAZINA KAO INHIBITORI TRK KINAZE
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ZA200708159B (en) 1-Acetic acid-indole derivatives with PDG2 antagonist activity
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
AR092289A1 (es) Derivados de aminoquinazolina y sus sales y metodos de uso
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer